Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab withdrawal study in polyarticular-course juvenile idiopathic arthritis
2009-011593-15Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in juvenile idiopathic arthritis (JIA) comparing Continued tocilizumab with Placebo withdrawal (2 arms). Primary endpoint: Primary efficacy of open-label tocilizumab therapy (Part I). Started Jul 2009; status: completed.
02
Drugs
tocilizumab
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2009-011593-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011593-15.